Articles

Metabolic map is made

By identifying metabolic abnormalities in people with schizophrenia, Finnish scientists take one step closer to a diagnostic test for the brain disorder
Written byLori Lesko
| 4 min read

HELSINKI, Finland—Scientists in Finland have taken a smallbut significant step toward developing a clinical test for diagnosingschizophrenia—and a giant leap for schizophrenics forced to live with the delusions,hallucinations and behavior that mark the chronic and severe brain disorder.

The key to this diagnostic breakthrough has come in a studyperformed by a team led by Matej Orešič, chief research scientist at the VTTTechnical Research Centre of Finland near Helsinki, in collaboration with JaanaSuvisaari from the Finnish National Institute for Health and Welfare.

These findings, published online March 23 in thepeer-reviewed journal Genome Medicine,may prove an important step towards the development of a clinical diagnostictest for schizophrenia.

Researchers found that rather than waiting for symptoms toappear, schizophrenia can be diagnosed by identifying specific metabolicabnormalities found in people with the disease.

This new knowledge is expected to help researchers learnabout the susceptibility, progression and treatment of schizophrenia, whichaffects 1 percent of the global population, including an estimated 2.7 millionAmericans.

To continue reading this article, subscribe for FREE toDrug Discovery News Logo

Subscribe today to keep up to date with the latest advancements and discoveries in drug development achieved by scientists in pharma, biotech, non-profit, academic, clinical, and government labs.

Add Drug Discovery News as a preferred source on Google

Add Drug Discovery News as a preferred Google source to see more of our trusted coverage.

About the Author

Here are some related topics that may interest you:

Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Gloved hand holding a multiwell cell culture plate under a fluorescence microscope for spheroid analysis.
Using confocal live-cell imaging to characterize immune-mediated cytotoxicity over time.
Fluorescence microscopy image of cells displaying green and red fluorescent signals.
Using confocal live-cell imaging to assess treatment effects in spheroids, organoids, and co-cultures.
3D illustration of Y-shaped antibody molecules floating against a soft blue background, with a detailed antibody structure in the foreground.
From molecular developability to functional activity, integrated characterization strategies help inform lead selection and optimization in biologics discovery.